Highest-materiality recent filing
Q1 rev $8.9M (+2%); net loss $5.1M; DrugSorb-ATR FDA submission delayed to late 2026/early 2027
Revenue $8.9M, +2% YoY; gross margin 69% vs 71% in Q1 2025.
CytoSorbents receives Nasdaq extension to Sept 28, 2026 for minimum bid price compliance
Received 180-day extension until Sept 28, 2026 to regain $1.00 minimum bid price compliance.
Revenue $37.1M (+4% YoY); gross margin 71%. Net loss improved to $8.2M ($0.13/sh) from $20.7M loss.
CytoSorbents Reports Q3 2025 Revenue of $9.5M, Up 10% YoY, and Provides Business Update
Revenue was $9.5 million for Q3 2025, a 10% increase from $8.6 million in Q3 2024, driven by record distributor sales.
CytoSorbents (CTSO) receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on Oct 2, 2025, for non-compliance with Minimum Bid Price Requirement.
FDA appeal upheld prior De Novo denial for DrugSorb-ATR, citing need for additional label-indication data; no safety issues found.
FDA upholds DrugSorb-ATR De Novo denial but offers path forward
FDA appeal decision found no safety issues with DrugSorb-ATR but upheld the prior De Novo denial.
CytoSorbents Q2 revenue $9.6M (+9% YoY); net income $1.9M but adjusted loss widens
Revenue $9.6M, up 9% YoY (4% constant currency); Germany sales up 22% YoY and sequentially.
CytoSorbents: FDA appeal hearing set; Health Canada refuses DrugSorb-ATR license
FDA confirmed appeal hearing under 21 CFR 10.75; supervisory review expected to complete by end of August 2025.
CytoSorbents appeals FDA denial of DrugSorb-ATR De Novo request; decision expected ~60 days
Appeal filed June 18, 2025 under 21 CFR 10.75; FDA denial letter dated April 25, 2025.
CytoSorbents Q1 product rev $8.7M (-3%); FDA denies DrugSorb-ATR De Novo
Product revenue $8.7M, flat constant currency vs Q1 2024 $9.0M; gross margin 71% vs 77%.
CytoSorbents receives FDA denial for DrugSorb-ATR De Novo; plans appeal if unresolved
FDA issued denial letter on April 25, 2025 for DrugSorb-ATR De Novo Request, citing remaining deficiencies.
CytoSorbents restates 2023/2024 financials due to inventory and RSU errors
Overstated inventory from clerical error; understated non-cash RSU expense due to using vesting-date fair value instead of grant-date.
CytoSorbents Q4 product rev $9.2M (+25% YoY); FY rev $35.6M (+15%); expects FDA decision 2025
Q4 product revenue $9.2M (+25% YoY); product gross margin 71%; operating loss improved 61% to $3.7M.
Earnings call rescheduled to March 31, 2025 at 4:30 PM ET; annual audit still in progress.
Q4 product revenue expected $9.0-9.2M (22-25% YoY growth); full-year $35.4-35.6M (~14% growth).
CytoSorbents raises $1.6M from Series A warrant exercises; total rights offering proceeds $7.85M
1,417,208 Series A Right Warrants exercised at $1.13 each for $1.6M gross proceeds upon expiration.
CytoSorbents closes oversubscribed rights offering, raises $6.25M, unlocks $5M restricted cash
Rights offering raised $6.25M gross from all 6.25M Units; oversubscribed 68% with 10.5M Units demanded.
Q4 2024 product revenue est $9.0M-$9.2M, 22-25% YoY growth vs $7.35M in Q4 2023.
CytoSorbents commences rights offering at $1.00/unit, expiring Jan 10, 2025
Record date Dec 16, 2024; one Subscription Right per share of common stock owned.
CytoSorbents launches rights offering of up to 6.25M units at $1.00 each
Record date Dec 16, 2024; basic rights expire Jan 10, 2025; subscription price $1.00 per unit.
CytoSorbents reports Q3 product revenue $8.6M (+11% YoY); net loss narrows to $2.3M
Product revenue $8.6M (+11% YoY); total revenue $9.4M; net loss $2.3M ($0.04/sh) vs $9.2M loss in Q3 2023.
CytoSorbents submits DrugSorb-ATR FDA De Novo for CABG bleeding; Q3 sales $8.3-8.5M
DrugSorb-ATR De Novo application submitted to FDA on Sept 27, 2024 for reducing perioperative bleeding in CABG patients on ticagrelor.
CytoSorbents authorizes up to $20M ATM equity offering of common stock
Company authorized offer and sale of up to $20M common stock under Open Market Sale Agreement with Jefferies LLC.
CytoSorbents appoints Peter J. Mariani as CFO; Kathleen P. Bloch retires
Peter J. Mariani appointed CFO effective Aug 14, 2024; previously CFO of Axogen (2016-2023).
CytoSorbents Q2 product sales up 10%, operating loss halved; DrugSorb-ATR submission on track
Total revenue $9.9M (+5% YoY); product sales $8.8M (+10%); gross margins improved to 75%.
CytoSorbents regains Nasdaq minimum bid price compliance
Received Nasdaq letter on July 26, 2024 confirming compliance after closing bid price at $1.00+ for 10 consecutive days through July 25.
CytoSorbents secures $20M credit facility with Avenue Capital; $10M available at close
Initial tranche $15M with $10M immediately available; $5M released upon FDA acceptance of DrugSorb-ATR De Novo.
CytoSorbents receives Nasdaq delisting notice for bid price below $1.00
Received Nasdaq notice on May 20, 2024 for non-compliance with Minimum Bid Price Requirement.
CytoSorbents Q1 product sales up 14% to $9.0M; gross margin expands to 76%
Product sales $9.0M, +14% YoY from $7.9M and +22% sequentially from Q4 2023 ($7.3M).
CytoSorbents executives take salary reduction; CEO by 35%, others by 15%
CEO Phillip Chan reduces salary by 35% ($123,498) to $359,353 through Dec 31, 2024.
CytoSorbents reports 10% core sales growth; plans DrugSorb-ATR submission in H2 2024
FY2023 total revenue $36.3M (+5% YoY); core CytoSorb sales $31.0M (+10%).
the Company also announced the retirement of Ms. Kathleen P. Bloch, the Company’s then serving Chief Financial Officer, and her transition into a consulting role with the Company.
On August 13, 2024, CytoSorbents Corporation (the “Company”) issued a press release announcing the appointment of Peter J. Mariani as the Company’s new Chief Financial Officer, effective as of August 14, 2024
Max materiality 0.80 · Median 0.65 · Most common event other_material